Neupogen

(filgrastim)

ApprovedProtein / enzyme

Filgrastim is used to help the body produce more white blood cells, which fight infections. It's commonly given to cancer patients undergoing chemotherapy whose immune systems are weakened.[2] Neupogen is currently approved and in use across 48 indications[4].[1]

Neupogen is one of 694 biologic programs targeting Soft Tissue Sarcoma. It is currently in Approved.

Indications

825

Total Trials

Active Trials

693

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Soft Tissue SarcomaCompleted

Bone Marrow TransplantationUnknown status

Sickle Cell DiseaseActive, not recruiting

Stem Cell TransplantTerminated

Glycogen Storage Disease IIActive, not recruiting

Glycogen Storage Disease Due to Acid Maltase DeficiencyActive, not recruiting

Tic DisorderActive, not recruiting

Ewing SarcomaActive, not recruiting

Pompe DiseaseActive, not recruiting

GrowthActive, not recruiting

Soft Tissue SarcomaPhase 2

Completed

Bone Marrow TransplantationPhase 3

Unknown status

Sickle Cell DiseasePhase 2

Active, not recruiting

Stem Cell TransplantPhase 2

Terminated

Glycogen Storage Disease IIPreclinical

Active, not recruiting

Glycogen Storage Disease Due to Acid Maltase DeficiencyPreclinical

Active, not recruiting

Tic DisorderPreclinical

Active, not recruiting

Ewing SarcomaPreclinical

Active, not recruiting

Pompe DiseasePreclinical

Active, not recruiting

GrowthPreclinical

Active, not recruiting

Showing 10 of 48 indications

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Neupogen

EEastern Cooperative Oncology Group

Zofran

2 3

Norvir

AbbVie

Preclinical

1 4

Cabenuva

GSK

Preclinical

1 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Rhabdomyosarcoma

NCT00077285

Q1 2027

Phase 1Recruiting

Chemotherapy

NCT05317403

Phase 1Not yet recruiting

Lymphoma

NCT07278856

Q3 2027

Phase 1/2Recruiting

Stem Cell Transplantation

NCT04224558

Q4 2027

Phase 1/2Active, not recruiting

Acute Myeloid Leukemia

NCT03247088

Clinical

Trials by Indication[1]

Lymphoma27 trials

A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma

Completed· Amgen logo

Amgen·Phase 2·NCT00117455

Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00086944·25 enrolled

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 2/3·NCT00070187·24 enrolled

Show 24 more trials

Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00002649·206 enrolled

Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00073931·25 enrolled

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003397·25 enrolled

High-Dose Chemotherapy in Treating Patients Undergoing Stem Cell Transplant for Recurrent or Refractory Hodgkin's Lymphoma

Completed·—·N/A·NCT00544570·30 enrolled

GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00521014·14 enrolled

Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00017381·30 enrolled

Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002691

Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma

Unknown status·GGerman Hodgkin's Lymphoma Study Group·Phase 3·NCT00025636·220 enrolled

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Completed·FFox Chase Cancer Center·Phase 2·NCT00003957·3 enrolled

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

Completed·UUniversity of California, San Francisco·N/A·NCT00416819·10 enrolled

TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 3·NCT00002757·1,148 enrolled

Aminocamptothecin in Treating Patients With T-cell Lymphoma

Completed·YYale University·Phase 2·NCT00002635·12 enrolled

Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

Completed·CChildren's Oncology Group·Phase 3·NCT01026220·166 enrolled

Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

Completed·—·Phase 2·NCT00265889·42 enrolled

Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00005631

Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma

Completed·TTemple University·Phase 1/2·NCT00002510

Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 2·NCT00070304·33 enrolled

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

Not yet recruiting·—·Phase 1·NCT07278856·20 enrolled

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

Terminated·—·Phase 2·NCT01746173·5 enrolled

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00003595·120 enrolled

Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01097057·20 enrolled

Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma

Completed·UUnknown Sponsor·Phase 3·NCT00052936·1,506 enrolled

Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00036855·36 enrolled

Combination Chemotherapy in Treating Children With Lymphoma

Completed·CChildren's Oncology Group·Phase 2·NCT00002590·221 enrolled

Breast Cancer22 trials

G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer

Completed·CCentre Francois Baclesse·Phase 2·NCT00771433·120 enrolled

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

Terminated·UUniversity of Nebraska·Phase 2·NCT00665457·3 enrolled

Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00012311

Show 19 more trials

A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy

Completed·OOttawa Hospital Research Institute·Phase 4·NCT04781959·233 enrolled

Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer

Completed·BBiocad·Phase 2·NCT01569087·60 enrolled

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer

Completed·FFred Hutchinson Cancer Center·Phase 3·NCT00003972·280 enrolled

S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT00015938·95 enrolled

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer

Unknown status·SSt. Louis University·Phase 1/2·NCT00002627·30 enrolled

High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00003032·224 enrolled

Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer

Completed·—·Phase 1·NCT00003927·15 enrolled

Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer

Terminated·—·Phase 1·NCT00346229·29 enrolled

Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer

Completed·NNCIC Clinical Trials Group·Phase 1·NCT00002866·50 enrolled

Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer

Completed·NNorthwestern University·Phase 1/2·NCT00006225

Monoclonal Antibody Therapy Plus Cyclosporine and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer

Unknown status·UUniversity of California, Davis·Phase 1·NCT00003920·18 enrolled

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer

Completed·NNorthwestern University·Phase 1·NCT00004174·30 enrolled

Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00020176

S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Completed·SSWOG Cancer Research Network·Phase 3·NCT00016406·399 enrolled

A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.

Completed·EEVIVE Biotechnology·Phase 2·NCT02521441·138 enrolled

Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer

Completed·YYale University·Phase 2·NCT00002679·89 enrolled

Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer

Unknown status·UUniversity of California, Davis·Phase 1·NCT00009763

Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00119262·226 enrolled

S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT00041067·76 enrolled

Multiple Myeloma12 trials

Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers

Unknown status·MMedical College of Wisconsin·Phase 2·NCT00003163·10 enrolled

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

Completed·UUniversity of Arkansas·Phase 3·NCT00083551·668 enrolled

Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma

Completed·—·Phase 1·NCT01074060·18 enrolled

Show 9 more trials

Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma

Completed· Sanofi logo

Sanofi·Phase 2·NCT02221479·14 enrolled

Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma

Unknown status·UUniversity of Pisa·Phase 3·NCT00932217·180 enrolled

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

Completed·UUniversity of Maryland, Baltimore·Phase 1/2·NCT00046852

S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma

Terminated·SSWOG Cancer Research Network·Phase 3·NCT00005834·19 enrolled

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Terminated·SSherif Farag, MB, BS·Phase 1/2·NCT01177683·32 enrolled

Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma

Completed·BBarbara Ann Karmanos Cancer Institute·N/A·NCT02037256·23 enrolled

Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma

Unknown status·CCommissie Voor Klinisch Toegepast Onderzoek·Phase 3·NCT00028886·450 enrolled

Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 3·NCT00008229

Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Completed·NNorthwestern University·Phase 3·NCT00004165

Acute Myeloid Leukemia9 trials

Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia

Suspended·—·Phase 1·NCT03467386·56 enrolled

S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Completed·SSWOG Cancer Research Network·Phase 2·NCT00066794·69 enrolled

Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT03247088·74 enrolled

Show 6 more trials

S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia

Completed·SSWOG Cancer Research Network·Phase 2·NCT00023777·71 enrolled

Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002719·500 enrolled

Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·CChildren's Oncology Group·Phase 1/2·NCT02642965·38 enrolled

Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00004215

Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

Completed·RRoswell Park Cancer Institute·Phase 1·NCT00093483·61 enrolled

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

Active, not recruiting·NNorthwestern University·Phase 1·NCT04250051·2 enrolled

Acute Lymphoblastic Leukemia6 trials

Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00022737·220 enrolled

S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·SSWOG Cancer Research Network·Phase 2·NCT00109837·79 enrolled

Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00039377·58 enrolled

Show 3 more trials

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2/3·NCT00720109·63 enrolled

Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00004862·24 enrolled

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00873093·148 enrolled

71 more indications

Germ Cell Tumor5 trials

Chemotherapy, Surgery, Radiation Therapy and Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Primary CNS Germ Cell Tumors

Unknown status·—·Phase 2·NCT00025324

Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00002559·43 enrolled

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00002558·108 enrolled

Show 2 more trials

Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors

Completed·CChildren's Oncology Group·Phase 2·NCT00467051·20 enrolled

Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors

Unknown status·UUniversity of Southampton·Phase 1/2·NCT00551122·23 enrolled

Leukemia5 trials

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002549·1,520 enrolled

Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00039130·105 enrolled

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia

Completed·UUniversity of Nebraska·Phase 2·NCT00002638·30 enrolled

Show 2 more trials

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00133991·23 enrolled

Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00357565·34 enrolled

Neuroblastoma5 trials

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma

Completed·CChildren's Oncology Group·Phase 3·NCT00004188·495 enrolled

131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma

Completed·UUniversity of California, San Francisco·Phase 2·NCT00293319·164 enrolled

Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma

Completed·CChildren's Oncology Group·Phase 1·NCT00070200·31 enrolled

Show 2 more trials

Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

Completed·CChildren's Oncology Group·Phase 3·NCT00567567·665 enrolled

Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00075634·21 enrolled

Stem Cell Transplantation5 trials

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors

Completed·CChildren's Oncology Group·Phase 1·NCT00003141·94 enrolled

High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003173·36 enrolled

Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00004061·111 enrolled

Show 2 more trials

Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00385788·52 enrolled

Stem Cell Transplantation in Crohn's Disease

Recruiting·—·Phase 1/2·NCT04224558·15 enrolled

Bone Marrow Transplantation4 trials

Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma

Completed·EEuropean Infant Neuroblastoma Study Group - 1999·Phase 2·NCT00025649

Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00053950·42 enrolled

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002515

Show 1 more trial

Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002634·45 enrolled

Stem Cell Transplant3 trials

Allogeneic Stem Cell Transplant for CLL

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT01629511·15 enrolled

Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT01658904·3 enrolled

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT00281879·200 enrolled

Soft Tissue Sarcoma3 trials

Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002764·340 enrolled

Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 1/2·NCT00023738

Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00089544·23 enrolled

Myelodysplastic Syndrome3 trials

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia

Completed·—·Phase 1/2·NCT00003619

Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00006040

Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed·CChildren's Oncology Group·Phase 2·NCT00002805·115 enrolled

Osteosarcoma3 trials

Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002539·214 enrolled

Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

Completed·CChildren's Oncology Group·Phase 1·NCT00742924·24 enrolled

Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00019864·100 enrolled

Fanconi Anemia3 trials

Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00258427·14 enrolled

Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00630253·31 enrolled

Gene Therapy for Fanconi Anemia

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT01331018·3 enrolled

Hematologic Malignancies3 trials

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

Terminated·AAlliance for Clinical Trials in Oncology·Phase 2·NCT01118013·6 enrolled

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02960646·11 enrolled

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT01028716·46 enrolled

Chronic Myelogenous Leukemia3 trials

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00002674·30 enrolled

Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00002868·744 enrolled

Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia

Unknown status·IIII. Medizinische Klinik Mannheim·Phase 3·NCT00025402·1,000 enrolled

Small Cell Lung Cancer3 trials

Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer

Unknown status·EEBMT Solid Tumors Working Party·Phase 3·NCT00011921·430 enrolled

Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00028925·27 enrolled

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Small Cell Lung Cancer

Completed·UUNICANCER·Phase 2·NCT00003860·36 enrolled

Chronic Lymphocytic Leukemia2 trials

Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia

Completed·GGerman CLL Study Group·Phase 2·NCT00275015·169 enrolled

Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003658·60 enrolled

Recurrent or Metastatic2 trials

Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer

Completed·RRoswell Park Cancer Institute·Phase 1·NCT00003294·24 enrolled

Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix

Completed·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00003065·25 enrolled

Chemotherapy2 trials

Venetoclax to Augment Epigenetic Modification and Chemotherapy

Recruiting·MMedical College of Wisconsin·Phase 1·NCT05317403·40 enrolled

Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00004853·34 enrolled

Metastatic Prostate Cancer2 trials

Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Unknown status·UUniversity of California, Davis·Phase 1·NCT00009750

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003400·45 enrolled

Primary Systemic Amyloidosis2 trials

High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003353

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Terminated·EEastern Cooperative Oncology Group·Phase 1·NCT00052884·8 enrolled

Bladder Cancer2 trials

Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00003105·30 enrolled

Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003133·30 enrolled

Fallopian Tube Cancer2 trials

Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer

Terminated·GGynecologic Oncology Group·Phase 1·NCT00003382

Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Completed·—·Phase 1·NCT00550784·8 enrolled

Non-Small Cell Lung Cancer2 trials

Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer

Withdrawn· GSK logo

GSK·Phase 1·NCT01938456

Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Unknown status· Amgen logo

Amgen·Phase 2·NCT00006215

Rhabdomyosarcoma2 trials

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

Completed·CChildren's Oncology Group·Phase 3·NCT00002995·483 enrolled

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00077285·65 enrolled

Bone Marrow Transplant2 trials

Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00118326

Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases

Completed·TThe Canadian Blood and Marrow Transplant Group·Phase 3·NCT00438958·230 enrolled

Brain Cancer2 trials

Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00014573

Combination Chemotherapy for Patients With Brain Cancer

Completed·—·Phase 2·NCT00002814·20 enrolled

Mantle Cell Lymphoma2 trials

Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma

Completed·WWashington University School of Medicine·Phase 1·NCT02728531·18 enrolled

Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00020943·79 enrolled

Advanced Cancer2 trials

Tumor Cell Vaccine in Treating Patients With Advanced Cancer

Completed·HHoag Memorial Hospital Presbyterian·Phase 2·NCT00002505

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

Terminated·JJonsson Comprehensive Cancer Center·Phase 1·NCT03240861·5 enrolled

Hodgkin's Disease2 trials

Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease

Completed·—·Phase 2·NCT00003114·5 enrolled

Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease

Completed·CChildren's Oncology Group·Phase 3·NCT00002827·294 enrolled

Neutropenia2 trials

Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia

Terminated· Novartis logo

Novartis·Phase 4·NCT01859637·6 enrolled

Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy

Completed·CChildren's Oncology Group·Phase 3·NCT00003739·67 enrolled

Medulloblastoma2 trials

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT00392327·379 enrolled

Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma

Completed·CChildren's Oncology Group·Phase 2·NCT00003573·53 enrolled

Gastrointestinal1 trial

Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer

Completed·MMontefiore Medical Center·Phase 2·NCT00019474·60 enrolled

Drug1 trial

Severe Bullous Drug Eruption and Filgrastim

Recruiting·HHospices Civils de Lyon·Phase 2/3·NCT04651439·42 enrolled

Immune Response1 trial

Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00006578

B-cell acute lymphoblastic leukemia1 trial

Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00381680·275 enrolled

Solid Tumors1 trial

Docetaxel in Treating Children With Recurrent Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00002825·20 enrolled

Autoimmune Disease1 trial

Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

Unknown status·—·N/A·NCT00006055·10 enrolled

Ewing's Sarcoma1 trial

Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor

Completed·CChildren's Oncology Group·Phase 3·NCT00006734·587 enrolled

Ovarian Cancer1 trial

Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00002977·45 enrolled

Natural Killer Cell1 trial

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00354172·16 enrolled

Solid Malignancies1 trial

Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT02392793·43 enrolled

Systemic Lupus Erythematosus1 trial

Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome

Completed·JJohns Hopkins University·N/A·NCT00010400·35 enrolled

Terminated·SStanford University·Phase 2·NCT00482053·3 enrolled

Acute Myeloid Leukaemia (AML)1 trial

Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)

Completed· Amgen logo

Amgen·Phase 2·NCT00114764·84 enrolled

Tic Disorder1 trial

Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders

Unknown status·—·N/A·NCT00006056·40 enrolled

Acute Myocardial Infarction1 trial

A Phase I - II Safety Study of Filgrastim (Neupogen) to Improve Left Ventricular Function After Severe Acute Myocardial Infarction

Completed·TThe Cleveland Clinic·Phase 1/2·NCT00215124

Anemia1 trial

Phase I Pilot Study of CD34 Enriched, Fanconi's Anemia Complementation Group C Gene Transduced Autologous Peripheral Blood Stem Cell Transplantation in Patients With Fanconi's Anemia

Unknown status·UUniversity of Minnesota·Phase 1·NCT00005896·6 enrolled

Malignant Glioma1 trial

Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma

Completed·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00008008·40 enrolled

Macroglobulinemia1 trial

S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia

Completed·SSWOG Cancer Research Network·Phase 2·NCT00003416·9 enrolled

Progressive Multifocal Leukoencephalopathy1 trial

Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001048·90 enrolled

Nosocomial Infection1 trial

Prevention Trial of Nosocomial Infections in Neutropenic Prematures With G-CSF

Completed·UUniversity Hospital, Strasbourg, France·Phase 3·NCT00213759·200 enrolled

Transplant Recipient1 trial

Tissue Repair in Stem Cell Transplant Recipients

Terminated·MM.D. Anderson Cancer Center·N/A·NCT00501228·2 enrolled

Angiosarcoma1 trial

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT05799612

Retinoblastoma1 trial

Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma

Withdrawn·—·N/A·NCT00980551

Paroxysmal Nocturnal Hemoglobinuria1 trial

Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00004464·69 enrolled

Myelodysplastic Syndromes1 trial

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT02044796·199 enrolled

Amyloidosis1 trial

2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis

Terminated·—·Phase 2·NCT00075608·12 enrolled

Advanced Sarcoma1 trial

Chemotherapy in Treating Patients With Advanced Sarcoma

Completed·SSwiss Cancer Institute·Phase 2·NCT00002526·20 enrolled

Cancer of the Esophagus1 trial

Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00009880

SCS1 trial

Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect

Completed·UUniversity of Kentucky·Phase 1/2·NCT00003425·25 enrolled

Cell Therapy1 trial

Proteomics and Stem Cell Therapy as a New Vascularization Strategy

Completed·UUniversity of Illinois at Chicago·N/A·NCT02802852·9 enrolled

Induction Chemotherapy1 trial

Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer

Completed·—·Phase 2·NCT01467115·1 enrolled

Lung Cancer1 trial

Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer

Completed·FFox Chase Cancer Center·Phase 2·NCT00021333·29 enrolled

Advanced Head and Neck Cancer1 trial

Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00023959·39 enrolled

Ependymoma1 trial

Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT01096368·479 enrolled

Acute Leukemia1 trial

Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00462787·23 enrolled

Severe Aplastic Anemia1 trial

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

Completed·—·Phase 1·NCT00054236·55 enrolled

Melanoma1 trial

S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma

Completed·SSWOG Cancer Research Network·Phase 3·NCT00006237·432 enrolled

Primitive Neuroectodermal Tumor1 trial

Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

Completed·SSt. Jude Children's Research Hospital·Phase 3·NCT00085202·416 enrolled

G-CSF1 trial

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00822770·47 enrolled

Unspecified3 trials

Pegfilgrastim PBPC Mobilization Study

Completed· Amgen logo

Amgen·Phase 2·NCT00066092·41 enrolled

NOX-A12 Multiple Ascending Dose Study in Healthy Volunteers

Completed·TTME Pharma AG·Phase 1·NCT01194934·12 enrolled

HD Melphalan and SCT in Patients With IGDD or LCDD

Terminated·—·Phase 2·NCT00681044·5 enrolled

Regulatory

FDA Approval Timeline[5]

Feb 20, 1991

NEUPOGEN

NDA BLA103353

Jun 15, 1994

NEUPOGEN

NDA BLA103353

Dec 19, 1994

NEUPOGEN

NDA BLA103353

Dec 28, 1995

NEUPOGEN

NDA BLA103353

Apr 2, 1998

NEUPOGEN

NDA BLA103353

Jun 21, 2001

NEUPOGEN

NDA BLA103353

May 29, 2002

NEUPOGEN

NDA BLA103353

Nov 24, 2004

NEUPOGEN

NDA BLA103353

Dec 17, 2004

NEUPOGEN

NDA BLA103353

Oct 25, 2006

NEUPOGEN

NDA BLA103353

Sep 27, 2007

NEUPOGEN

NDA BLA103353

Mar 2, 2010

NEUPOGEN

NDA BLA103353

May 25, 2012

NEUPOGEN

NDA BLA103353

Sep 13, 2013

NEUPOGEN

NDA BLA103353

Feb 6, 2015

NEUPOGEN

NDA BLA103353

Mar 30, 2015

NEUPOGEN

NDA BLA103353

Jul 30, 2015

NEUPOGEN

NDA BLA103353

Jun 29, 2016

NEUPOGEN

NDA BLA103353

Jun 18, 2018

NEUPOGEN

NDA BLA103353

Jan 5, 2021

NEUPOGEN

NDA BLA103353

Feb 4, 2021

NEUPOGEN

NDA BLA103353

Apr 18, 2023

NEUPOGEN

NDA BLA103353

Apr 18, 2025

NEUPOGEN

NDA BLA103353

Jul 16, 2026

NEUPOGEN

NDA BLA103353

Sources

References

[1]
ClinicalTrials.gov — 825 trial records for filgrastim. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Neupogen drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — filgrastim compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for filgrastim. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA BLA103353). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Eastern Cooperative Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Granulocyte Colony Stimulating Factor Receptor Agonist[3]
Modality: Protein / enzyme[3]
Highest Phase: Approved[1]
Company: EEastern Cooperative Oncology Group

Neupogen

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Lymphoma27 trials

Breast Cancer22 trials

Multiple Myeloma12 trials

Acute Myeloid Leukemia9 trials

Acute Lymphoblastic Leukemia6 trials

Germ Cell Tumor5 trials

Leukemia5 trials

Neuroblastoma5 trials

Stem Cell Transplantation5 trials

Bone Marrow Transplantation4 trials

Stem Cell Transplant3 trials

Soft Tissue Sarcoma3 trials

Myelodysplastic Syndrome3 trials

Osteosarcoma3 trials

Fanconi Anemia3 trials

Hematologic Malignancies3 trials

Chronic Myelogenous Leukemia3 trials

Small Cell Lung Cancer3 trials

Chronic Lymphocytic Leukemia2 trials

Recurrent or Metastatic2 trials

Chemotherapy2 trials

Metastatic Prostate Cancer2 trials

Primary Systemic Amyloidosis2 trials

Bladder Cancer2 trials

Fallopian Tube Cancer2 trials

Non-Small Cell Lung Cancer2 trials

Rhabdomyosarcoma2 trials

Bone Marrow Transplant2 trials

Brain Cancer2 trials

Mantle Cell Lymphoma2 trials

Advanced Cancer2 trials

Hodgkin's Disease2 trials

Neutropenia2 trials

Medulloblastoma2 trials

Gastrointestinal1 trial

Drug1 trial

Immune Response1 trial

B-cell acute lymphoblastic leukemia1 trial

Solid Tumors1 trial

Autoimmune Disease1 trial

Ewing's Sarcoma1 trial

Ovarian Cancer1 trial

Natural Killer Cell1 trial

Solid Malignancies1 trial

Systemic Lupus Erythematosus1 trial

Chondrosarcoma1 trial

Diffuse Large B-Cell Lymphoma1 trial

Phase 21 trial

Acute Myeloid Leukaemia (AML)1 trial

Tic Disorder1 trial

Acute Myocardial Infarction1 trial

Anemia1 trial

Malignant Glioma1 trial

Macroglobulinemia1 trial

Progressive Multifocal Leukoencephalopathy1 trial

Nosocomial Infection1 trial

Transplant Recipient1 trial

Angiosarcoma1 trial

Retinoblastoma1 trial

Paroxysmal Nocturnal Hemoglobinuria1 trial

Myelodysplastic Syndromes1 trial

Amyloidosis1 trial

Advanced Sarcoma1 trial

Cancer of the Esophagus1 trial

SCS1 trial

Cell Therapy1 trial

Induction Chemotherapy1 trial

Lung Cancer1 trial

Advanced Head and Neck Cancer1 trial

Ependymoma1 trial

Acute Leukemia1 trial